AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 42(6), 1990, pp. 527-531
Copyright © 1990 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, D. M.
Right arrow Articles by Chulay, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, D. M.
Right arrow Articles by Chulay, J. D.

Safety and Immunogenicity of a Plasmodium vivax Sporozoite Vaccine

Daniel M. Gordon, Thomas M. Cosgriff, Imogene Schneider, Gail F. Wasserman, William R. Majarian, Michael R. Hollingdale AND Jeffrey D. Chulay
Walter Reed Army Institute of Research, Washington, DC; United States Army Medical Institute of Infectious Diseases, Fort Detrick, Maryland; SmithKline Beecham Pharmaceuticals, Swedeland, Pennsylvania; Biomedical Research Institute, Rockville, Maryland

A recombinant DNA Plasmodium vivax sporozoite vaccine containing the repeating region of the Salvador I strain circumsporozoite (CS) protein was produced in Escherichia coli. This vaccine was tested in 13 naive volunteers at doses of 10–1,000 µg. No serious adverse reactions were noted. None of 4 volunteers receiving the 10 µg dose developed antibodies measurable by ELISA. Six of 9 volunteers in the other dose groups developed measurable antibodies: 5 of 5 volunteers receiving 100 µg and 1 of 4 receiving 1,000 µg. Antibody responses measured by immunofluorescence assays paralleled those seen by ELISA. None of the volunteers developed antisera that inhibited sporozoite invasion of human hepatoma cells in vitro. Lack of a classical anamnestic response and lack of a typical dose response to increasing amounts of antigen suggests the possible presence of an immunosuppressive epitope in the repetitive region of the CS protein.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
W. R. Ballou and C. P. Cahill
Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 289 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. Yadava, J. Sattabongkot, M. A. Washington, L. A. Ware, V. Majam, H. Zheng, S. Kumar, and C. F. Ockenhouse
A Novel Chimeric Plasmodium vivax Circumsporozoite Protein Induces Biologically Functional Antibodies That Recognize both VK210 and VK247 Sporozoites
Infect. Immun., March 1, 2007; 75(3): 1177 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
J. A. BONILLA, L. VALIDUM, R. CUMMINGS, and C. J. PALMER
GENETIC DIVERSITY OF PLASMODIUM VIVAX PVCSP AND PVMSP1 IN GUYANA, SOUTH AMERICA
Am J Trop Med Hyg, November 1, 2006; 75(5): 830 - 835.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
S. Hoffman, V Nussenzweig, J. Sadoff, and R. Nussenzweig
Progress toward malaria preerythrocytic vaccines
Science, April 26, 1991; 252(5005): 520 - 521.
[PDF]

Home page
 ScienceHome page
Y Charoenvit, W. Collins, T. Jones, P Millet, L Yuan, G. Campbell, R. Beaudoin, Broderson JR, and S. Hoffman
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence
Science, February 8, 1991; 251(4994): 668 - 671.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Society of Tropical Medicine and Hygiene.